GlaxoSmithKline PLC (GSK): Price and Financial Metrics


GlaxoSmithKline PLC (GSK): $37.78

0.28 (+0.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GSK POWR Grades


  • Value is the dimension where GSK ranks best; there it ranks ahead of 97.43% of US stocks.
  • GSK's strongest trending metric is Momentum; it's been moving down over the last 197 days.
  • GSK ranks lowest in Momentum; there it ranks in the 2nd percentile.

GSK Stock Summary

  • GSK has a higher market value than 97.61% of US stocks; more precisely, its current market capitalization is $100,972,305,319.
  • Glaxosmithkline Plc's stock had its IPO on July 9, 1986, making it an older stock than 92.37% of US equities in our set.
  • In terms of volatility of its share price, GSK is more volatile than merely 2.3% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Glaxosmithkline Plc, a group of peers worth examining would be BP, TGT, CI, SYK, and BTI.
  • GSK's SEC filings can be seen here. And to visit Glaxosmithkline Plc's official web site, go to www.gsk.com.

GSK Stock Price Chart Interactive Chart >

Price chart for GSK

GSK Price/Volume Stats

Current price $37.78 52-week high $43.18
Prev. close $37.50 52-week low $33.26
Day low $37.65 Volume 1,402,200
Day high $37.81 Avg. volume 5,821,135
50-day MA $36.27 Dividend yield 6.72%
200-day MA $37.45 Market Cap 101.73B

GlaxoSmithKline PLC (GSK) Company Bio


GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company’s wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.

GSK Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$37.78$18.7 -50%

We started the process of determining a valid price forecast for Glaxosmithkline Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Glaxosmithkline Plc ranked in the 38th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 49.5%. As for the metrics that stood out in our discounted cash flow analysis of Glaxosmithkline Plc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 7.87; that's higher than 60.5% of US stocks in the Healthcare sector that have positive free cash flow.
  • Glaxosmithkline Plc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than just 22.63% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-51%
1%-50%
2%-50%
3%-49%
4%-49%
5%-48%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as GSK, try BPMC, EGRX, A, AMGN, and ABC.


GSK Latest News Stream


Event/Time News Detail
Loading, please wait...

GSK Latest Social Stream


Loading social stream, please wait...

View Full GSK Social Stream

Latest GSK News From Around the Web

Below are the latest news stories about Glaxosmithkline Plc that investors may wish to consider to help them evaluate GSK as an investment opportunity.

Voltaren Arthritis Pain Gel Empowers Early Morning Risers Living with Osteoarthritis

GSK Consumer Healthcare (LSE/NYSE: GSK), the makers of Voltaren Arthritis Pain Gel (diclofenac sodium topical gel, 1%) today revealed new data that uncovers a painful truth: for people with osteoarthritis (OA), mornings can be the most difficult part of the day. The study, conducted by OnePoll on behalf of Voltaren, found that among 1,000 people with OA surveyed, 67% of Americans reported their joint pain makes it difficult for them to get out of bed in the morning based on their activities from the previous day. This May, national Arthritis Awareness Month, Voltaren is empowering those with joint pain and stiffness to feel the joy of movement and help them take on their day.

Yahoo | May 3, 2021

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

Yahoo | May 3, 2021

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates

Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD ) Nuplazid failed to get label expansion to include the indication of dementia-related psychosis. The FDA did not keep its tryst with the decision dates for ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD ) pain drug and Sol-Gel Technologies Ltd.'s (NASDAQ: SLGL ) investigational skin inflammation treatment. Protalix BioTherapeutics, Inc.'s (NASDAQ: PLX ) Fabry disease treatment candidate also faced rejection at the FDA altar. The regulatory agency extended the review period for Pfizer Inc.'s (NYSE: PFE ) atopic dermatitis drug. On the other hand, Supernus Pharmaceuticals, Inc.'s (NASDAQ: SUPN ) attention deficit hyperactivity drug ...

Benzinga | May 1, 2021

California has lowest COVID-19 case rate in the U.S.: RPT

Dr. James Simmons, Hospitalist Nurse Practitioner in Los Angeles, CA, joins Yahoo Finance’s Sibile Marcellus and Alexis Christoforous to discuss the latest on the coronavirus.

Yahoo | April 30, 2021

Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs

Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.

Yahoo | April 30, 2021

Read More 'GSK' Stories Here

GSK Price Returns

1-mo 4.89%
3-mo 9.06%
6-mo 5.75%
1-year -6.00%
3-year 10.34%
5-year 15.84%
YTD 4.49%
2020 -17.79%
2019 29.12%
2018 13.70%
2017 -3.03%
2016 -1.10%

GSK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GSK Dividend History

Continue Researching GSK

Here are a few links from around the web to help you further your research on Glaxosmithkline Plc's stock as an investment opportunity:

Glaxosmithkline Plc (GSK) Stock Price | Nasdaq
Glaxosmithkline Plc (GSK) Stock Quote, History and News - Yahoo Finance
Glaxosmithkline Plc (GSK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8934 seconds.